Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer

Human Pathology

Volumn 42, Issue 7, 2011, Pages 983-990

  Tapia, Coya ^a,d   Zlobec, Inti ^a   Schneider, Sandra ^a   Kilic, Ergin ^b   Güth, Uwe ^c   Bubendorf, Lukas ^a   Kim, Suwon ^d,e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; FISH; HER2 neu; ING4; Tumor suppressor gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INHIBITOR OF GROWTH 4 PROTEIN; PROGESTERONE RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; FEMALE; GENE DELETION; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79959356720     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.10.012     Document Type: Article

References (34)

1. Shiseki M, Nagashima M, Pedeux RM, et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 2003;63: 2373-8. (Pubitemid 36605171)
2. Zhang X, Xu LS, Wang ZQ, et al. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 2004;570:7-12. (Pubitemid 38900947)
3. Kim S, Chin K, Gray JW, Bishop JM. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A 2004;101: 16251-6. (Pubitemid 39552831)
4. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004;428:328-32. (Pubitemid 38418804)
5. Shen JC, Unoki M, Ythier D, et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 2007;67:2552-8. (Pubitemid 46548940)
6. Ozer A, Wu LC, Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A 2005;102:7481-6. (Pubitemid 40740997)
7. Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 2007;110: 4464-75. (Pubitemid 351377813)
8. Cavé H, Gérard B, Martin E, et al. Loss of heterozygosity in the chromosomal region 12p12-13 is very common in childhood acute lymphoblastic leukemia and permits the precise localization of a tumor-suppressor gene distinct from p27KIP1. Blood 1995;86: 3869-75.
9. Hatta Y, Takeuchi S, Yokota J, Koeffler HP. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br J Cancer 1997;75:1256-62. (Pubitemid 27179813)
10. Kawana Y, Ichikawa T, Suzuki H, et al. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 2002;53: 60-4. (Pubitemid 34966864)
11. Gunduz M, Nagatsuka H, Demircan K, et al. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005:356.
12. Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008;29: 1373-9.
13. Li M, Jin Y, Sun WJ, Yu Y, Bai J, Tong DD, et al. Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol 2009;219:87-95.
14. Fang F, Luo LB, Tao YM, Wu F, Yang LY. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:409-16.
15. Nozell S, Laver T, Moseley D, et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol 2008;28:6632-45.
16. Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007;60:768-72. (Pubitemid 47056905)
17. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16. (Pubitemid 34517647)
18. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-90. (Pubitemid 46291811)
19. Tapia C, Schraml P, Simon R, et al. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 2004;25:1551-7.
20. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
21. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
22. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 530-6.
23. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8 [Epub 2008 Apr 2314].
24. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23 [Epub 2003 Jun 8426].
25. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9. (Pubitemid 38821193)
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. 235 1987:4785.
27. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
28. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26:3637-43. (Pubitemid 46842713)
29. Doyon Y, Cayrou C, Ullah M, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006;21:51-64. (Pubitemid 43017848)
30. Hung T, Binda O, Champagne KS, et al. ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Mol Cell 2009;33:248-56.
31. Palacios A, Muñoz IG, Pantoja-Uceda D, et al. Molecular basis of histone H3K4me3 recognition by ING4. J Biol Chem 2008;283: 15956-64.
32. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027-31. (Pubitemid 30159714)
33. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20:1287-99. (Pubitemid 32269934)
34. Biswas DK, Shi Q, Baily S, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42 [Epub 12004 Jun 10125].